ASOCIACIÓN MÉDICA CENTRO MÉDICO ABC

Local cover image
Local cover image
Image from Google Jackets

Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial / Max J. Schmulson, Jazmin Chiu-Ugalde, Adolfo Sáez-Ríos, Aurelio López-Colombo, Gualberto J. Mateos-Pérez, José María Remes-Troche, Sergio Sobrino-Cossio, Julio C. Soto-Pérez, José L. Tamayo de la Cuesta, José L. Tamayo de la Cuesta, Oscar T. Teramoto-Matsubara, Juan C. López-Alvarenga,

By: Material type: ArticleArticlePublication details: 2020Content type:
  • texto
Media type:
  • computadora
Carrier type:
  • recurso en línea
Subject(s): Online resources: In: Journal of clinical gastroenterology 2020; volumen 54, número 4: páginas 30-31.Summary: Goals: We aimed to evaluate the efficacy and safety of PB+S (pinaverium bromide 100 mg plus simethicone 300 mg) in patients with irritable bowel syndrome (IBS). Background: IBS is a multifactorial disorder; thus, combination therapy with different mechanisms of action is expected to be useful. PB+S has shown effectiveness in an open-label clinical study in IBS. However, there are no placebo-controlled trials. Materials and methods: IBS-Rome III patients with abdominal pain/discomfort for at least 2 days within the week prior to baseline assessment were included in this 12-week, randomized, double-blind, placebo-controlled study of PB+S versus placebo, bid. The primary endpoint was overall symptom improvement, evaluated weekly by the patient (Likert Scale). Secondary endpoints included the weekly improvement in the severity of abdominal pain and bloating assessed both by patients (10-cm Visual Analogue Scale) and investigators (Likert Scale); frequency of Bristol Scale stool types (consistency) evaluated by patients and the IBS Quality of Life scores. Results: A total of 285 patients (female: 83%; 36.5±8.9 y old) received at least 1 dose of PB+S (n=140) or placebo (n=145). No difference was observed in overall symptom improvement between the groups (P=0.13). However, PB+S was superior in abdominal pain (effect size: 31%, P=0.038) and bloating (33%, P=0.019). Patients with IBS-C and IBS-M showed the best improvement in the frequency of stool types with PB+S. No differences were observed in IBS Quality of Life scores and adverse events. Conclusions: PB+S was superior to placebo in improving abdominal pain and bloating in patients with active IBS. The effect on the frequency of stool consistency was particularly significant in IBS-C and IBS-M.
Holdings
Cover image Item type Current library Collection Call number Status Date due Barcode
Revista electrónica Revista electrónica Repositorio Institucional Repositorio Institucional Available R00132

Goals: We aimed to evaluate the efficacy and safety of PB+S (pinaverium bromide 100 mg plus simethicone 300 mg) in patients with irritable bowel syndrome (IBS).
Background: IBS is a multifactorial disorder; thus, combination therapy with different mechanisms of action is expected to be useful. PB+S has shown effectiveness in an open-label clinical study in IBS. However, there are no placebo-controlled trials.
Materials and methods: IBS-Rome III patients with abdominal pain/discomfort for at least 2 days within the week prior to baseline assessment were included in this 12-week, randomized, double-blind, placebo-controlled study of PB+S versus placebo, bid. The primary endpoint was overall symptom improvement, evaluated weekly by the patient (Likert Scale). Secondary endpoints included the weekly improvement in the severity of abdominal pain and bloating assessed both by patients (10-cm Visual Analogue Scale) and investigators (Likert Scale); frequency of Bristol Scale stool types (consistency) evaluated by patients and the IBS Quality of Life scores.
Results: A total of 285 patients (female: 83%; 36.5±8.9 y old) received at least 1 dose of PB+S (n=140) or placebo (n=145). No difference was observed in overall symptom improvement between the groups (P=0.13). However, PB+S was superior in abdominal pain (effect size: 31%, P=0.038) and bloating (33%, P=0.019). Patients with IBS-C and IBS-M showed the best improvement in the frequency of stool types with PB+S. No differences were observed in IBS Quality of Life scores and adverse events.
Conclusions: PB+S was superior to placebo in improving abdominal pain and bloating in patients with active IBS. The effect on the frequency of stool consistency was particularly significant in IBS-C and IBS-M.

Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, López-Colombo A, Mateos-Pérez GJ, Remes-Troche JM, Sobrino-Cossio S, Soto-Pérez JC, Tamayo de la Cuesta JL, Teramoto-Matsubara OT, López-Alvarenga JC. Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial. J Clin Gastroenterol. 2020;54(4):30-39. Disponible en: https://journals.lww.com/jcge/Fulltext/2020/04000/Efficacy_of_the_Combination_of_Pinaverium_Bromide.2.aspx

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image

Powered by Koha